MedPath

Betaine Anhydrous

These highlights do not include all the information needed to use BETAINE ANHYDROUS FOR ORAL SOLUTION safely and effectively. See full prescribing information for BETAINE ANHYDROUS FOR ORAL SOLUTION. BETAINE ANHYDROUS FOR ORAL SOLUTION Initial U.S. Approval: 1996

Approved
Approval ID

ee8a95c3-df9f-6e55-e053-2a95a90ab17b

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 18, 2023

Manufacturers
FDA

Eton Pharmaceuticals, Inc.

DUNS: 080870465

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Betaine Anhydrous

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code71863-115
Application NumberANDA210508
Product Classification
M
Marketing Category
C73584
G
Generic Name
Betaine Anhydrous
Product Specifications
Route of AdministrationORAL
Effective DateDecember 18, 2023
FDA Product Classification

INGREDIENTS (1)

BETAINEActive
Quantity: 1 g in 1 g
Code: 3SCV180C9W
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Betaine Anhydrous - FDA Drug Approval Details